Tafamidis Treated-Overall vs Tafamidis Untreated-Overall: Number of All-Cause Deaths
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0627 | 0.0539 | 0.0728 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.183 | 0.173 | 0.193 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.12 | -0.133 | -0.106 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.343 | 0.292 | 0.403 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.299 | 0.251 | 0.357 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Tafamidis Treated-Overall than on Tafamidis Untreated-Overall | 8.34 | 7.5 | 9.46 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Tafamidis Treated-Overall | All available data from participants who had been enrolled in THAOS, signed the informed consent and who received tafamidis treatment on or prior to the date of enrollment in THAOS. All available data from first dose of tafamidis until final treatment discontinuation of tafamidis or end of follow-up in THAOS (whichever was earlier) for participant who received tafamidis at the time of enrollment in THAOS but subsequently initiated treatment with tafamidis. For outcome measures, a participant could be reported in both the tafamidis untreated and tafamidis treated sets if the participant initiated treatment with tafamidis after beginning participation in THAOS. | 158 | 2,521 | OG000 | ClinicalTrials.gov |
| Group 2 | Tafamidis Untreated-Overall | All available data from participants who had been enrolled in THAOS, signed the informed consent and who had not received tafamidis during the THAOS study; and for those participants who were not on tafamidis during or after initial enrollment in THAOS but then started receiving tafamidis post enrollment, all available data collected before receiving the first dose of tafamidis while in THAOS. Available data after a participant discontinued treatment with tafamidis were excluded. | 1,038 | 5,686 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of All-Cause Deaths | ClinicalTrials.gov |
| Description | Number of deaths due to any cause was analyzed as time from enrollment or first treatment of tafamidis. | ClinicalTrials.gov |
| Time frame | From the start of data collection at Baseline (Day 1) to the end of data collection (Up to 14.4 years) | ClinicalTrials.gov |
| Population | Tafamidis treated set included participants who were on tafamidis at or prior to the enrollment, as well as participants who were not on tafamidis at enrollment but subsequently initiated tafamidis treatment during the study. Tafamidis untreated set included participants who were enrolled and never received tafamidis throughout the study, as well as participants who were not on tafamidis before or at enrollment but subsequently initiated tafamidis treatment during the study. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Transthyretin Amyloidosis Outcome Survey (THAOS) | ClinicalTrials.gov |
| NCT number | NCT00628745 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Transthyretin Gene Mutations, Transthyretin Amyloidosis | ClinicalTrials.gov |
| Interventions | None. Observational Study. | ClinicalTrials.gov |
| Lead sponsor | Pfizer | ClinicalTrials.gov |
| Results first posted | 2024-11-22 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00628745?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.